Shares in Beijing-based Sinovac Biotech (Nasdaq: SVA) are up 1% after morning trading in New York, following the news that Sinobioway Consortium has upped its offer to buy the firm, from $7 to $8 per share.
Sinobioway, a group of Chinese investment firms focused on healthcare, submitted verification of the financial basis for the offer two weeks ago, upon request.
The consortium is engaged in a long-running bidding war with another group of investors, led by Sinovac chief executive Weidong Yin and Indian venture capitalists SAIF Partners.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze